The latest announcement is out from BeiGene Ltd ( (HK:6160) ).
BeiGene, Ltd. has announced the internet availability of its proxy materials in accordance with regulatory requirements, as published on the U.S. Securities and Exchange Commission’s website. This announcement underscores the company’s commitment to transparency and regulatory compliance, potentially impacting its corporate governance and investor relations positively.
More about BeiGene Ltd
BeiGene, Ltd. is a biotechnology company that focuses on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company operates in the global pharmaceutical industry, with a significant market focus on oncology therapeutics.
YTD Price Performance: 39.38%
Average Trading Volume: 3,000,976
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: HK$223.1B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.